- In early August 2026, Globus Medical reported second-quarter 2026 results showing sales of US$789.61 million, up from US$745.34 million a year earlier, while net income decreased to US$151.57 million from US$202.85 million and diluted EPS from continuing operations eased to US$1.10 from US$1.49.
- For the first half of 2026, sales grew to US$1.55 billion from US$1.34 billion, yet net income and diluted EPS from continuing operations were roughly flat versus the prior year, highlighting that higher revenue did not translate into higher profitability over the period.
- With revenue rising but earnings under pressure, we’ll explore how this margin picture influences Globus Medical’s investment narrative and outlook.
Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
Globus Medical Investment Narrative Recap
To own Globus Medical, you need to believe that demand for spine and musculoskeletal solutions, plus adoption of its robotics and navigation platforms, will support durable growth. The latest results show revenue moving higher while margins compress, which makes near term execution on cost control and acquisition integration the key catalyst, and leaves sustained pressure on profitability as the most immediate risk. This quarter’s numbers do not fundamentally change that balance, but they sharpen the focus on margins.
In May 2026, Globus reaffirmed its full year 2026 revenue outlook of US$3.18 billion to US$3.22 billion, even before reporting first half sales of US$1.55 billion. That earlier guidance now sits against a backdrop of rising sales but weaker earnings in the second quarter, making delivery on both the top line target and margin improvement especially important as investors weigh the impact of the NuVasive and Nevro integrations.
Yet investors should also be aware that ongoing pricing pressure on hospitals and payers could...
Read the full narrative on Globus Medical (it's free!)
Globus Medical's narrative projects $3.7 billion revenue and $685.2 million earnings by 2029.
Uncover how Globus Medical's forecasts yield a $107.42 fair value, a 32% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming revenues around US$3.8 billion and earnings near US$684 million by 2029, which is far rosier than consensus, so after this margin squeeze you may want to compare those bullish expectations with more cautious views on pricing pressure and procedure volumes.
Explore 5 other fair value estimates on Globus Medical - why the stock might be worth just $82.00!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Globus Medical research is our analysis highlighting 5 key rewards that could impact your investment decision.
- Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com